Are Two CGRP Blockers Better Than One? Evaluating Dual Anti-CGRP Therapy for Chronic Migraine
Dual CGRP pathway antagonism (combining anti-CGRP antibodies with gepants or different anti-CGRP mechanisms) shows potential for chronic migraine, particularly in patients who partially respond to monotherapy.
Quick Facts
What This Study Found
Dual CGRP pathway antagonism shows potential for chronic migraine through complementary mechanisms, with emerging evidence supporting combination anti-CGRP antibody + gepant approaches in partial responders.
Key Numbers
How They Did This
Review evaluating the rationale, evidence, and safety considerations for dual CGRP antagonism in chronic migraine treatment.
Why This Research Matters
Up to 50% of chronic migraine patients don't adequately respond to single anti-CGRP therapy. Dual targeting could help these patients.
The Bigger Picture
Dual CGRP targeting parallels the evolution in oncology where combination therapies often outperform monotherapy by targeting multiple nodes in a pathway.
What This Study Doesn't Tell Us
Limited clinical evidence for dual approaches. Safety of combining CGRP blockers unknown. Cost implications significant.
Questions This Raises
- ?What is the optimal combination of anti-CGRP agents?
- ?Is there a safety ceiling for CGRP pathway blockade?
- ?Which patients would benefit most from dual therapy?
Trust & Context
- Key Stat:
- Two targets, one pathway Combining anti-CGRP antibodies with gepants could provide more complete CGRP pathway blockade for resistant migraine
- Evidence Grade:
- Review of emerging evidence. Strong mechanistic rationale but limited clinical data for combination approaches.
- Study Age:
- Published in 2025.
- Original Title:
- Evaluating dual calcitonin gene-related peptide antagonists for chronic migraine prevention.
- Published In:
- Headache (2026)
- Authors:
- Graves, Kara S, To, Jason, Paige, Hayley, Kennedy, Amanda G, Sprouse-Blum, Adam S, Devine, Derek, MacDougall, Julie
- Database ID:
- RPEP-15229
Evidence Hierarchy
Frequently Asked Questions
Can I take two CGRP blockers for migraines?
Emerging evidence suggests combining different types of CGRP blockers (like an antibody injection with an oral gepant) might help patients who partially respond to one alone. Discuss with your neurologist.
Is it safe to block CGRP from two directions?
The safety of dual CGRP blockade is still being studied. CGRP has protective functions in the body, so the safety ceiling for pathway suppression needs careful evaluation.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15229APA
Graves, Kara S; To, Jason; Paige, Hayley; Kennedy, Amanda G; Sprouse-Blum, Adam S; Devine, Derek; MacDougall, Julie. (2026). Evaluating dual calcitonin gene-related peptide antagonists for chronic migraine prevention.. Headache. https://doi.org/10.1111/head.70057
MLA
Graves, Kara S, et al. "Evaluating dual calcitonin gene-related peptide antagonists for chronic migraine prevention.." Headache, 2026. https://doi.org/10.1111/head.70057
RethinkPeptides
RethinkPeptides Research Database. "Evaluating dual calcitonin gene-related peptide antagonists ..." RPEP-15229. Retrieved from https://rethinkpeptides.com/research/graves-2026-evaluating-dual-calcitonin-generelated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.